Tandem Diabetes Care, Inc.

NasdaqGM TNDM

Tandem Diabetes Care, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 14.91

Tandem Diabetes Care, Inc. Revenue Per Share is USD 14.91 for the Trailing 12 Months (TTM) ending September 30, 2024, a 25.08% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Tandem Diabetes Care, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 11.92, a -3.58% change year over year.
  • Tandem Diabetes Care, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 12.36, a 17.19% change year over year.
  • Tandem Diabetes Care, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 10.55, a 44.57% change year over year.
  • Tandem Diabetes Care, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 7.30, a 28.34% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NasdaqGM: TNDM

Tandem Diabetes Care, Inc.

CEO Mr. John F. Sheridan
IPO Date Nov. 14, 2013
Location United States
Headquarters 11075 Roselle Street
Employees 2,400
Sector Health Care
Industries
Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

PACB

Pacific Biosciences of California, Inc.

USD 1.85

-7.96%

INSP

Inspire Medical Systems, Inc.

USD 169.99

-3.10%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

SYK

Stryker Corporation

USD 362.80

0.50%

ABT

Abbott Laboratories

USD 113.02

-0.15%

MDT

Medtronic plc

USD 85.25

4.23%

NNOX

Nano-X Imaging Ltd.

USD 7.48

1.22%

PEN

Penumbra, Inc.

USD 252.89

2.41%

BSX

Boston Scientific Corporation

USD 95.65

1.10%

ALGN

Align Technology, Inc.

USD 210.46

-1.51%

StockViz Staff

January 15, 2025

Any question? Send us an email